J. Safra Sarasin Holding AG Has $69.74 Million Position in Amgen Inc. $AMGN

J. Safra Sarasin Holding AG increased its stake in Amgen Inc. (NASDAQ:AMGN) by 2.8% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 247,128 shares of the medical research company’s stock after purchasing an additional 6,833 shares during the period. Amgen accounts for 1.1% of J. Safra Sarasin Holding AG’s portfolio, making the stock its 22nd largest holding. J. Safra Sarasin Holding AG’s holdings in Amgen were worth $69,740,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently bought and sold shares of AMGN. Legacy Investment Solutions LLC acquired a new position in shares of Amgen during the second quarter valued at $27,000. Evelyn Partners Investment Management LLP bought a new stake in Amgen during the 2nd quarter worth about $32,000. Howard Hughes Medical Institute acquired a new position in Amgen during the 2nd quarter valued at about $32,000. Quaker Wealth Management LLC lifted its position in Amgen by 200.0% during the 2nd quarter. Quaker Wealth Management LLC now owns 120 shares of the medical research company’s stock valued at $34,000 after purchasing an additional 240 shares during the period. Finally, Nvwm LLC boosted its stake in shares of Amgen by 893.3% in the 2nd quarter. Nvwm LLC now owns 149 shares of the medical research company’s stock valued at $42,000 after purchasing an additional 134 shares during the last quarter. 76.50% of the stock is currently owned by institutional investors.

Amgen Price Performance

AMGN opened at $349.69 on Tuesday. The stock has a market cap of $188.30 billion, a P/E ratio of 27.02, a P/E/G ratio of 3.06 and a beta of 0.45. Amgen Inc. has a 12 month low of $261.43 and a 12 month high of $350.43. The company has a quick ratio of 0.99, a current ratio of 1.28 and a debt-to-equity ratio of 5.45. The company has a fifty day simple moving average of $332.23 and a 200 day simple moving average of $308.04.

Amgen (NASDAQ:AMGN) last posted its earnings results on Tuesday, November 4th. The medical research company reported $5.64 earnings per share for the quarter, topping the consensus estimate of $5.01 by $0.63. Amgen had a return on equity of 162.59% and a net margin of 19.47%.The firm had revenue of $9.56 billion for the quarter, compared to analyst estimates of $8.98 billion. During the same period in the previous year, the company posted $5.58 earnings per share. The company’s revenue for the quarter was up 12.4% on a year-over-year basis. Amgen has set its FY 2025 guidance at 20.600-21.400 EPS. On average, research analysts expect that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, February 13th will be given a $2.52 dividend. The ex-dividend date is Friday, February 13th. This represents a $10.08 annualized dividend and a dividend yield of 2.9%. This is a boost from Amgen’s previous quarterly dividend of $2.38. Amgen’s payout ratio is presently 73.57%.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on AMGN shares. Sanford C. Bernstein downgraded shares of Amgen from an “outperform” rating to a “market perform” rating and set a $335.00 price target for the company. in a research note on Tuesday, January 20th. Daiwa Capital Markets upped their target price on shares of Amgen from $310.00 to $370.00 and gave the company an “outperform” rating in a research report on Tuesday, November 18th. HSBC reissued a “buy” rating and issued a $425.00 price target on shares of Amgen in a research note on Wednesday, December 10th. Argus lifted their price objective on Amgen from $310.00 to $360.00 and gave the stock a “buy” rating in a research note on Tuesday, December 30th. Finally, Guggenheim upped their price objective on Amgen from $288.00 to $305.00 and gave the company a “neutral” rating in a report on Thursday, November 6th. One research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $339.71.

Insiders Place Their Bets

In other Amgen news, EVP Murdo Gordon sold 6,879 shares of Amgen stock in a transaction that occurred on Wednesday, November 12th. The shares were sold at an average price of $336.83, for a total value of $2,317,053.57. Following the transaction, the executive vice president owned 41,923 shares of the company’s stock, valued at approximately $14,120,924.09. The trade was a 14.10% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, SVP Rachna Khosla sold 890 shares of the company’s stock in a transaction that occurred on Wednesday, November 12th. The shares were sold at an average price of $336.24, for a total transaction of $299,253.60. Following the completion of the transaction, the senior vice president owned 7,082 shares of the company’s stock, valued at $2,381,251.68. This trade represents a 11.16% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 10,908 shares of company stock worth $3,674,966. Company insiders own 0.69% of the company’s stock.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.